StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)

Close on Nov 17, 2026Market cap $287.64MP/E –Yield –

Emergent BioSolutions total assets

Total assets on the balance sheet at the end of each period.

Emergent BioSolutions's total assets was $995.20M at Sep 30, 2026. For fiscal 2025 it was $1.32B, down 5.1% from the year before. Over ten years it grew 2.4% a year on average. The highest annual figure on record is $3.17B in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.32B-5.1%
FY2024Dec 31, 2024$1.39B-23.8%
FY2023Dec 31, 2023$1.82B-42.4%
FY2022Dec 31, 2022$3.17B+7.1%
FY2021Dec 31, 2021$2.96B+2.6%
FY2020Dec 31, 2020$2.88B+23.9%
FY2019Dec 31, 2019$2.33B+4.4%
FY2018Dec 31, 2018$2.23B+108.3%
FY2017Dec 31, 2017$1.07B+10.3%
FY2016Dec 31, 2016$970.11M-6.5%
FY2015Dec 31, 2015$1.04B+10.5%
FY2014Dec 31, 2014$938.69M+49.8%
FY2013Dec 31, 2013$626.63M+11.1%
FY2012Dec 31, 2012$564.23M+3.2%
FY2011Dec 31, 2011$546.86M+9.3%
FY2010Dec 31, 2010$500.32M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$995.20M-31.9%
Q2 FY2026Jun 30, 2026$1.12B-21.2%
Q1 FY2026Mar 31, 2026$1.32B-7.4%
Q4 FY2025Dec 31, 2025$1.32B-5.1%
Q3 FY2025Sep 30, 2025$1.46B-1.1%
Q2 FY2025Jun 30, 2025$1.42B-6.4%
Q1 FY2025Mar 31, 2025$1.43B-20.9%
Q4 FY2024Dec 31, 2024$1.39B-23.8%
Q3 FY2024Sep 30, 2024$1.48B-21.9%
Q2 FY2024Jun 30, 2024$1.51B-30.5%
Q1 FY2024Mar 31, 2024$1.80B-38.9%
Q4 FY2023Dec 31, 2023$1.82B-42.4%
Q3 FY2023Sep 30, 2023$1.89B-34.6%
Q2 FY2023Jun 30, 2023$2.18B-20.3%
Q1 FY2023Mar 31, 2023$2.95B+6.1%
Q4 FY2022Dec 31, 2022$3.17B+7.1%
Q3 FY2022Sep 30, 2022$2.90B+1.0%
Q2 FY2022Jun 30, 2022$2.74B-6.2%
Q1 FY2022Mar 31, 2022$2.78B-4.1%
Q4 FY2021Dec 31, 2021$2.96B+2.6%
Q3 FY2021Sep 30, 2021$2.87B+9.6%
Q2 FY2021Jun 30, 2021$2.92B+18.2%
Q1 FY2021Mar 31, 2021$2.90B+27.3%
Q4 FY2020Dec 31, 2020$2.88B+23.9%
Q3 FY2020Sep 30, 2020$2.62B+12.1%
Q2 FY2020Jun 30, 2020$2.47B+6.2%
Q1 FY2020Mar 31, 2020$2.28B+5.8%
Q4 FY2019Dec 31, 2019$2.33B+4.4%
Q3 FY2019Sep 30, 2019$2.33B+98.9%
Q2 FY2019Jun 30, 2019$2.32B+103.8%
Q1 FY2019Mar 31, 2019$2.15B+101.6%
Q4 FY2018Dec 31, 2018$2.23B+108.3%
Q3 FY2018Sep 30, 2018$1.17B+14.6%
Q2 FY2018Jun 30, 2018$1.14B+17.4%
Q1 FY2018Mar 31, 2018$1.07B+12.3%
Q4 FY2017Dec 31, 2017$1.07B+10.3%
Q3 FY2017Sep 30, 2017$1.02B–
Q2 FY2017Jun 30, 2017$970.48M–
Q1 FY2017Mar 31, 2017$951.64M–
Q4 FY2016Dec 31, 2016$970.11M–

More Emergent BioSolutions figures

See a number that looks wrong?